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Phase I studies are critical in the overall process of drug development. This phase is a key point at which the bridge from animal to human studies occurs, and the studies offer the first opportunity to investigate the drug in humans. There are many uncertainties and much to be taken into consideration when planning and executing a first-time-in-human study. It is an ample opportunity to learn as much as possible as early as possible, and if the study is appropriately designed and evaluated, there is a great deal of information to collect, even in a small study.
In the past decade, there has been much focus on the optimization of early drug development, and many articles advocating the need of formalization of phase I studies and the implementation of more statistically based designs have been published. [1] [2] [3] [4] [5] Within cancer research, formal statistical methods such as the continual reassessment method 6 are being used today, and there is hope that the methods developed in the cancer area can be modified and applied to dose-escalation trials in other therapeutic areas and studies involving healthy volunteers. The opportunity to collect more information early in the development phase can lead to a shortened development time and reduced develop-
First-time-in-human studies are small, time-lagged doseescalation studies including volunteer subjects evaluating safety and tolerability. There is little consensus in the design of a first-time-in-human study, and it is difficult to get an overview of studies performed. One hundred five studies comprising 3323 healthy volunteers published in the 5 major clinical pharmacology journals since 1995 were analyzed. The average trial was placebo controlled, double blind including 32 subjects at 5 dose levels but with great variation in cohort size and dose-escalation method. The parallel singledose design was the most common design, with the crossover
ment costs. But to optimize phase I trials, one must first understand how they are being performed today.
Today, there appears to be as many methods of conducting first-time-in-human studies as there are pharmaceutical companies and scientific and academic institutions, and the method chosen is more a result of habit and preference than a well-founded scientific and statistical rationale. There seems to be no consensus on how to perform first-time-in-human studies in healthy volunteers, and, as expected not all phase I studies are published 7 ; it is difficult to get an overall picture on the world of first-time-in-human studies.
The objective of this article is to outline the detailed design of all phase I dose-escalation trials involving healthy volunteers published in the 5 major clinical pharmacology journals during the past decade to show what phase I dose-escalation studies are being performed and how. We hope this might give a foundation for discussion and debate on the design of first-time-inhuman studies.
METHODS

Five major clinical pharmacology journals, British Journal of Clinical Pharmacology, Clinical Pharmacology and Therapeutics, European Journal of Clinical
Pharmacology, International Journal of Clinical Pharmacology and Therapeutics, and Journal of Clinical Pharmacology, were selected and scanned for publications of phase I dose-escalation trials (firsttime-in-human studies). All issues published in the 10-year period from January 1, 1995, to December 31, 2004 , were examined manually, and the articles were selected based on title and abstract.
The selection criteria were phase I dose-escalation studies involving healthy volunteers. If the identified study was not a first-time-in-human study and the actual first-time-in-human dose-escalation study had been published elsewhere, this study was recovered and included in the analysis. If the identified study were indeed the first published dose-escalation study (eg, preceded by a small pilot study, whether published or not), it was included in the analysis, but had the study been preceded by a larger phase I study or an unpublished dose-escalation trial, the study was excluded from the analysis. The method resulted in the identification of 105 studies published in 72 articles.
The studies were then analyzed based on therapeutic area, size, blinding and control, study design, dose escalation, cohort size, and distribution of subjects within the cohorts. Of the phase I dose-escalation studies included in the analysis, most were published in 1 of the 5 selected journals. Only 4 of the studies were published in other journals and identified based on references.
As control, an advanced MEDLINE search was performed searching for articles published since January 1995 with titles/abstracts containing the phrases phase 1, phase I, healthy volunteers, or safety and tolerability, excluding all cancer trials. The search resulted in 2707 hits, 98 of which were judged to be phase I doseescalation studies based on title and/or abstract. Based on the control, it is sufficient to conclude that the 72 articles recovered from the 5 journals are representative of the overall publication of phase I trials in the selected time period.
RESULTS
A total of 72 publications comprising 105 studies and representing 50 different organizations/institutes were recovered from the 5 international journals and identified as phase I dose-escalation trials in healthy subjects (Table I) . Eighty-five of the 105 studies were absolute first-time-in-human studies. All major therapeutic areas were represented in the studies; grouping the studies according to the World Health Organization's Anatomical Therapeutic Chemical (ATC) classification system, 11 of the 14 groups at level 1 were represented (all but dermatologicals, sensory systems, and varia; Table II ). At level 2 of the ATC classification system, the 105 studies could be sorted into 28 subgroups, with the largest group, analgesics, containing 11 studies and 6 groups containing only 1 study.
The distribution over time of the studies published in the period studied is illustrated in Figure 1 . A large majority (86 studies; 81.9%) of the studies were placebo controlled, and 66 (62.9%) of them were double blind. Eleven of the studies (10.8%) were single blind, 13 were open, and for 15 of the studies (14.7%), the degree of blinding was not stated in the publication. The studies comprised a total of 3323 healthy volunteers ranging from 108 to 4 subjects per study ( Figure 2) ; the average number of subjects in a study was 31.65, and the median was 28.
The studies show a great variation in the cohort sizes and distribution of subjects within the cohorts. The cohorts consisted of 2 to 16 subjects, with 30 as the extreme exception in 1 study. 59 The most abundant cohort size was 8 subjects, usually with 6 subjects allocated to active treatment and 2 to placebo, a distribution implemented in 29 of the studies. Figure 3 displays the distribution of subjects within the cohorts for the studies and the number of studies in which the particular distribu- tion is applied. In 4 of the studies, 9,16,61 the distribution of active and placebo-treated subjects was not stated in the article.
The dose-escalation scheme did also vary between the studies. The number of dose levels investigated in the studies ranged from only 2 up to 19, with most (86.7%) of the studies investigating 7 dose levels or fewer (Figure 4) . The average number of dose levels used in the studies was 5.24, and the median value was 5.
Various dose-escalation schemes were employed in the studies. They could be categorized as linear, logarithmic, modified Fibonacci, or miscellaneous, including escalation regimens in which the 3 standardized methods are combined. A linear escalation method, in which the dose increment is fixed, is used in 12 of the studies. Twenty-two of the studies used a logarithmic dose-escalation scheme, in which the relative dose increment is the same, for example, 100%. The modified Fibonacci escalation method is frequently used in cancer phase I trials 3, [78] [79] [80] and has also to some extent been implemented in phase I dose-escalation trials in healthy volunteers; 4 of the studies are using a modified version of the Fibonacci sequence. However, most (67 studies, or 63.8%) of the dose-escalation schemes reported do not seem to follow one particular model. Some are a combination of 2 of the models described above (eg, starting with a logarithmic escalation to convert into a modified Fibonacci sequence), while for other studies, there is no apparent scheme and the doses seem to be arbitrarily chosen.
Five major study design types could be identified among the studies (Table I, Figure 5 ). In the most common parallel single-dose design (Figure 5a with new subjects is included and administered the next dose. A variation of this design is the parallel multiple-dose design (Figure 5b) , in which the subjects are administered multiple doses at the same dose level. But again, a new cohort is included for each dose level. The parallel single-and multiple-dose design ( Figure  5c ) is a combination of the 2 previously described. After the safety evaluation, which generally is based on single-dose data from more than 1 dose level, the single dose is followed by a multiple administration of the same dose within the same cohort. In the crossover studies, each subject receives various dose levels of the substance. In the grouped crossover studies with 1 or more dose groups, the doses are crossed within each group (Figure 5d ). All subjects within a cohort receive the same doses in the same order, and a placebo is randomized among the drug administrations. Between each dose administration, there is a safety evaluation and a washout period. The number of groups, number of dose levels within a group, and the cohort size in the group can vary. In the alternate crossover design, the dose escalation is alternated between 2 or more groups (Figure 5e ). Each group receives every other (or third, etc) dose, and during the dosing of one cohort, the other cohort(s) are in washout. Within the cohort, placebo administration can be randomized, either to the same person throughout the study or in a rotating manner. Six of the studies were not possible to characterize, either because the exact subject allocation was not reported in the article 75, 77 or because an idiosyncratic design was applied. 10, 58, 76 The parallel single-dose design was the most recurrent among the designs identified, implemented in 52 of the 105 studies (49.5%). Nineteen (18.1%) of the studies were parallel multiple-dose studies (Table I) .
The studies with a more elaborate design, with several different doses administered to each subject, were less frequent. Eight studies (7.8%) could be categorized as alternating crossover studies, 14 (13.7%) were grouped crossover studies with 1 or more groups, and 6 (5.9%) studies were combined single-and multipledose escalation studies (Table I) .
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DISCUSSION
First-time-in-human studies are pivotal in the drug development process; they present the researchers' first opportunity to study the substance in its target species and can present a lot of data if designed appropriately. The increasing cost of drug development has brought increased focus to processes developed for the purpose of optimizing, rationalizing, and increasing the capacity of and eliminating redundancies in clinical trials without compromising safety. The efforts have been collectively gathered under the motto "New Safe Medicines Faster" in Europe and "The Critical Path" in the United States. 81 The distribution of the studies over the time period illustrated in Figure 1 shows a trend toward an increase in the number of studies published in the most recent years. During the past decade, several articles have appeared that advocate the need for better publication ethics and improved reporting of clinical trials, 7, [82] [83] [84] and it appears that the number of phase I trials being published is indeed increasing. However, most of the first-time-in-human studies published are still cancer trials, and there exists no record on how many phase I studies are actually being performed; hence, it is not certain whether the observed publication increase is due to an increase in the number of phase I trials performed or actually a result of better publication ethics. Certainly there might be a publication bias in the reporting of first-time-in-human studies, but the many studies published during the past decade should still be able to provide an ample image of the way these studies are being performed. Time delay may be another confounding factor. Many of the studies were performed quite recently prior to publication date, but several were performed a long time before they were published. It might be possible that the studies performed today are different from the studies published today, but as the time period studied is large (10 years) and little has changed during this period, the survey should provide a representative picture of the modern first-time-in-human studies.
The studies investigated were sponsored by both industry and academia, and the study designs differ just as much within the 2 groups. Most of the studies are double blind, and only for a small percentage of the studies is there no information on the degree of blinding. But 15 studies is still too much, and as even the small phase I trials investigated here are clinical trials, the blinding should be reported in the publication.
The use of placebo in phase I trials has been debated, [85] [86] [87] but the majority (82%) of the first-time-inhuman studies are placebo controlled. Of the 19 that are not, only 3 studies involved 28 subjects or more; most of the studies that were not placebo controlled were thus relatively small studies.
There was a large variation in the number of subjects investigated in each trial, but with the average number of subjects just exceeding 30 and most of the studies (77%) involving 40 subjects or fewer, it is clear that the studies are small and manageable. Of course, the total number of subjects in a dose-escalation trial depends on the number of dose levels investigated, but when looking at the number of subjects per dose level for the studies investigated (Figure 6 ), although there is still much variation (from 0.42 subjects per dose level to 16), in 74% of the studies only 8 or fewer subjects are tested per dose level.
Despite the small studies and the small cohorts, almost every possible combination of active and placebo treatments within a cohort is implemented. In light of the disparity, 1 combination comes through as the most abundant. There seems to be some consensus around the 6 + 2 distribution, which is applied in 29 studies. The use of at least 6 active subjects has been recommended, 88 and it is comforting to see that although the studies are small, the cohorts are large enough to yield conclusive data. The small size of the first-time-inhuman studies results in reduced power and predictability. Thus, it is important to adapt the design of the studies to obtain as much and as reliable information as possible. By increasing the cohort size by just 1 or 2 subjects, there is much to gain in power and detectability, especially if the cohort size is very small (fewer than 6 subjects). 88 The number of dose levels investigated seems to have no connection with the escalation scheme employed, and most of the studies do not appear to follow any particular escalation scheme. Instead, the entire dose escalation seems rather arbitrarily based on starting dose and stopping dose, with the other dose levels spread out in between.
The starting and stopping doses chosen depend on safety and toxicology preclinical data and are expected to be quite individual based on substance, therapy area, animal models, and method of starting dose selection. There are several publications discussing the optimal starting dose selection, 89, 90 and the US Food and Drug Administration has issued a draft guidance 91 on the estimation of the starting dose. But once the starting dose is selected, by whichever method chosen and based on the preclinical data, the actual escalation scheme will determine which and how many doses are administered.
The modified Fibonacci escalation is frequently used in cancer trials to allow for a rapid escalation in the lower doses and a more moderate escalation in the higher doses, and it seems to be gaining ground in ordinary phase I trials as well. The dose escalations in cancer phase I trials are moving toward more formal methods 92, 93 including the continual reassessment method, 6 in which the doses administered are based on the results from the previous dose levels. The demands on a regular phase I trial with healthy volunteers are not as high as on a cancer phase I trial involving patients, but the formal methods developed for cancer trials can be considered as an illustration of what can be achieved in any first-time-in-human study and can perhaps promote the development of similar, but more complex, methods for studies in healthy volunteers. Within the 11 therapeutic areas investigated in the studies, all 5 major study designs were represented. The largest ATC group was "nervous system," with 34 studies within 6 subgroups ( Figure 7a) . As exemplified by the nervous system, the distributions of the designs were evenly spread within most of the therapeutic areas. The only exception was "blood and blood-forming organs," and antithrombotic agents in particular (Figure 7b) . Of the 14 studies in substances affecting blood and the blood-forming system, 13 were parallel, and 12 were parallel single dose. The largest subgroup was anticoagulants, with 7 parallel single-dose studies. The absence of crossover designs in this group can be explained by the concern for carryover effects; when studying an anticoagulating drug, the outcome of too high a plasma concentration could be fatal, and one wants to avoid any risk of carryover effects.
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Of the 5 major study designs identified, the parallel single-dose design was the most frequent within all therapeutic areas; it was applied in almost half of the 105 studies. But it is also the most conservative design, with each subject receiving 1 administration of only 1 dose, and with the traditional parallel design, one cannot directly differentiate intrasubject variability from intersubject variability, as is possible if the substance is administered on more than 1 occasion. The crossover designs-grouped crossover and alternating crossovertake a more novel approach and allow for the investigational product to be administered more than once to each subject. They allow for more information to be obtained from fewer subjects and are more efficient in estimating dose proportionality. [94] [95] [96] Yin and Chen used mixed-effect modeling to evaluate first-time-in-human design alternatives for their precision in estimating dose proportionality, 97 and they concluded that an alternate design always requires fewer subjects to achieve the same precision compared to a sequential design. This is also the case in the studies investigated here. In Figure 6 , the number of subjects per dose level is depicted for the parallel single-dose studies, the crossover studies, and the alternating crossover studies. The number of subjects needed per dose level and also the total number of studies varies greatly, but it is evident that for parallel studies, the number of subjects included in the studies is much larger than for the 2 other designs.
There might be some inclination toward viewing the 2 latter (crossover and alternating crossover studies) as the more experimental and preferable studies, as they allow for more information to be gathered using fewer subjects, thus saving both time and money. However, looking at the publication timeline for the 3 study designs, this is not the case. Most of the studies are parallel single-dose studies, and they seem to be increasing rather than decreasing. In Figure 8 , the 3 studies are compared over the time period studied; for clarity, the 2 crossover designs are viewed together as "novel designs."
It appears that the experimental novel study designs were more frequent in the past, and most of the newly published studies are of traditional parallel design. The reasons for this might be many, including practical and logistical reasons such as volunteer recruitment/ interest in relation to multiple revisits to the clinical unit; fear of carryover effects, as noted for the antithrombotic agents; or packaging and randomization of clinical drug supply. However, it seems that despite ongoing discussions on "new safe medicines faster" and "optimizing phase I trials," phase I dose-escalation trials are still conservative and seem to be based more on habit and preferences than experimental and scientific rationale.
The development of study designs and evaluation methods for first-time-in-human cancer trials has been extensive in the past years, and this might also rub off on first-time-in-human studies in healthy volunteers. In cancer trials, the formal statistically based methods are gaining ground, and the future for dose-escalation trials in healthy volunteers looks bright. With open minds, extended power calculations, and methods adding more statistical rationales to these trial designs, we will be able to optimize phase I trials and develop our new safe medicines faster.
CONCLUSIONS
The design of first-time-in-human studies in healthy volunteers seems to be very arbitrary. There is great variation in number of dose levels, escalation methods, cohort sizes and distribution, and treatment allocation. The majorities of the designs are conservative and seem to be based on habit and preference instead of the statistical and scientific rationale needed to optimize the first-time-in-human studies. With a good overview of the way the trials are performed today, there is a base for continued discussion on the design of first-time-inhuman studies in healthy volunteers. 
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